

# 1 **Computer-delivered Cognitive Training and Transcranial Direct** 2 **Current Stimulation in Patients with HIV-associated Neurocognitive** 3 **Disorder: A Randomized Trial**

4 **Raymond L. Ownby<sup>1\*</sup> and Jae Kim<sup>1</sup>**

5 <sup>1</sup>Department of Psychiatry and Behavioral Medicine, Nova Southeastern University, Fort Lauderdale,  
6 Florida, USA

7 **\* Correspondence:**

8 Dr. Ownby

9 ro71@nova.edu

10 **Keywords: transcranial direct current stimulation, computer-delivered cognitive training,**  
11 **human immunodeficiency virus, cognition, HIV-associated neurocognitive disorder, mild**  
12 **neurocognitive disorder**

## 13 **Abstract**

14 **Objective:** HIV infection is associated with impaired cognition, and as individuals grow older, they  
15 may also experience age-related changes in mental abilities. Previous studies have shown that  
16 computer-based cognitive training (CCT) and transcranial direct current stimulation (tDCS) may be  
17 useful in improving cognition in older persons. This study evaluated the acceptability of CCT and  
18 tDCS to older adults with HIV-associated neurocognitive disorder, and assessed their impact on  
19 reaction time, attention, and psychomotor speed.

20 **Methods:** In a single-blind randomized study, 46 individuals with HIV-associated mild  
21 neurocognitive disorder completed neuropsychological assessments and six 20-minute training  
22 sessions to which they had been randomly assigned to one of the following conditions: (1) CCT with  
23 active tDCS; (2) CCT with sham tDCS, or (3) watching educational videos with sham tDCS.  
24 Immediately after training and again one month later, participants completed follow-up assessments.  
25 Outcomes were evaluated via repeated measures mixed effects models.

26 **Results:** Participant ratings of the intervention were positive. Effects on reaction time were not  
27 significant, but measures of attention and psychomotor speed suggested positive effects of the  
28 intervention.

29 **Conclusion:** Both CCT and tDCS were highly acceptable to older persons with HIV infection. CCT  
30 and tDCS may improve cognitive in affected individuals.

31 Registered at ClinicalTrials.gov (NCT03440840).

## 32 **1 Introduction**

33 While there has been significant progress in the treatment of HIV infection using multiple  
34 antiretroviral medications, HIV-association neurocognitive disorders (HANDs) continue to be seen in  
35 affected individuals, even when their viral loads are nondetectable (Heaton et al., 2010). HANDs are  
36 clinically significant because of their impact on patients' everyday functioning [1-3], medication

37 adherence [1, 4, 5], and quality of life [6-9]. In older persons, HANDs may have an additive or even  
38 synergistic effect in older persons, combining the influences of chronic HIV infection and cognitive  
39 aging [10, 11].

40 Few treatments are available for HAND. Stimulants can improve cognition in HAND but may be  
41 abused by vulnerable individuals and have undesirable adverse effects [12]. Other medications  
42 treatments have been studied, but none has demonstrated clear efficacy [13-18]. Other researchers  
43 have suggested that computer-delivered cognitive training (CCT) may be useful in HAND [19-21],  
44 but specialized CCT software is not always readily available or affordable. Further, many programs  
45 created for CCT are not inherently interesting, reducing users' motivations for continued use after  
46 completing a study for which they were compensated. Another approach may be to use computer  
47 gaming software that is already available as a CCT intervention [22, 23]. CCT software developers  
48 have sought to increase the inherent interest in their programs through gamification [24] to enhance  
49 their inherent interest, but many computer games are on the market now and often available at little  
50 or no cost. In addition, existing games depend on sustained use by players for their commercial  
51 success. Games such as these are interesting to players and include elements that engage them. First-  
52 person shooters (in which players use weapons to shoot at fictional enemies) can affect sustained  
53 attention and reaction time [24], however, some players may object to this type of game's violent  
54 content [24, 25].

55 Another established genre are games that provide players the simulated experience of car racing.  
56 These games require attention and psychomotor speed while using content that may be less  
57 objectionable. Use of one car racing game, created for a research study, was associated with better  
58 mental functioning in older persons [26]. Other researchers have commented on the possible  
59 usefulness of commercial computer games in addressing mental functioning in persons 50 years of  
60 age and older [23, 27-30]. Car racing games can engage and hold players' interest, potentially  
61 allowing them to continue cognitive training over extended periods. Researchers have shown that an  
62 off-the-shelf game that demanded mental speed resulted in longer use by older individuals when  
63 compared to a typical CCT program [29, 30]. Game play has been related to long-term mental  
64 training results, with effects evident in other cognitive domains besides those specifically trained  
65 [31]. Gaming has been shown, for example, to have a positive impact on the ability to regulate and  
66 direct mental processes [26]. Games may thus be effective for training and can engage users in a  
67 sustained fashion.

68 Transcranial direct current stimulation (tDCS) in combination with CCT has been shown to improve  
69 cognitive functioning [32-38]. tDCS is implemented by applying moistened sponge electrodes to a  
70 person's scalp and passing through a very small direct current (1-2 mA). tDCS research has shown  
71 that it can have a positive impact on various mental abilities, including verbal problem solving [39],  
72 working memory [40-42], and learning [43, 44].

73 How tDCS affects mental function is not definitively established, however, it has been shown to  
74 stimulate brain-derived neurotrophic growth factor (BDNF) in the motor cortex [45]. This may be  
75 especially relevant in treating persons with HAND as BDNF is affected in HIV infection [46, 47],  
76 and implicated in cognitive decline in older persons [48]. Increases in BDNF might be expected to  
77 exert a positive effect on mental functioning in persons with HAND.

78 We previously completed a pilot study of game-based CCT comparing its combination with active  
79 and sham tDCS in persons 50 years and older with HAND [49]. Results suggested that the  
80 intervention was acceptable to participants and that it may have had positive effects on their attention

81 and working memory. In the follow-up study reported here, we further explore the acceptability and  
82 efficacy of a game-based CCT intervention combined with tDCS in older persons with HIV  
83 infection. We hypothesized that CCT with tDCS would be acceptable to persons 50 years of age and  
84 older with HAND. We also hypothesized that CCT would be associated with improved reaction time,  
85 psychomotor speed, and attention and that the combination of active tDCS with CCT would be  
86 superior to CCT alone.

## 87 **2 Methods**

### 88 **2.1 Participants**

89 Participants were individuals 50 years of age and older with HIV infection. Diagnosis of HAND was  
90 established through review of recent laboratory results, clinical evaluation, and neuropsychological  
91 testing. All participants stated they subjectively experienced cognitive difficulties and, after  
92 assessment, were found to have impairment of mental functioning in two or more cognitive domains  
93 while not having dementia, thus meeting Frascati criteria for mild neurocognitive disorder [15].  
94 Potential participants were excluded if they had characteristics that might have increased risk to them  
95 from tDCS, such as seizures or bipolar disorder [50, 51]. Use of many psychotropic medications was  
96 also an exclusion criterion, as the pharmacologic activity of many of these drugs can affect tDCS [52,  
97 53]. Medications that were exclusions included those affecting serotonin, such as many  
98 antidepressants, dopamine, such as stimulants and antipsychotics, and gamma-amino butyric acid,  
99 such as benzodiazepines. Left-handed participants were excluded as our intent was to stimulate the  
100 dominant dorsolateral prefrontal cortex.

### 101 **2.2 Procedures**

#### 102 **2.2.1 Recruitment and determination of eligibility**

103 Participants were first recruited from individuals who had been in a previous study. We also recruited  
104 from local service providers for persons with HIV. A number of participants referred friends or  
105 acquaintances. We distributed flyers in several areas of Broward County, Florida, known to have a  
106 high prevalence of HIV infection, as well as advertising in a local newspaper and creating a  
107 Facebook page.

108 Interested individuals were contacted for a telephone interview to establish that they had complaints  
109 of cognitive difficulties, using questions published by the European AIDS Clinical Society [54]. In  
110 this interview, we inquired about use of medications that might lead to exclusion, and whether the  
111 person was willing to be in a study of CCT and tDCS. All were being treated for HIV infection and  
112 had been on their current medication regimen for at least the past month. Individuals who, from this  
113 telephone interview, appeared likely to be eligible were asked to come to our offices for individual  
114 assessment.

115 At this assessment, potential participants completed a series of cognitive assessments (marked with  
116 an asterisk in Table 1). The battery was selected to allow evaluation of areas often affected in  
117 HANDs [55]. Attention and working memory were evaluated with the Digit Span subtests of the  
118 Wechsler Adult Intelligence Scale, 4th edition, or WAIS-IV [56]. Psychomotor speed was evaluated  
119 with the Coding subtest of the WAIS-IV and Grooved Pegboard Test [57]. Executive function was  
120 measured with the Trail Making Test, Part B [58]. Verbal fluency was assessed with the Verbal  
121 Fluency test of the Delis-Kaplan Executive Function System [59]. Verbal learning and memory were

122 assessed with the Hopkins Verbal Learning Test—Revised or HVLTR [60], and visual learning and  
123 memory with the Brief Visuospatial Memory Test, or BVMT-R [61].

124 Cognitive impairment for the purpose of establishing the diagnosis of mild neurocognitive disorder  
125 was defined as a score in at least two ability areas that was below population norms by at least one  
126 standard deviation. Participants were treated for HIV infection that included ongoing laboratory  
127 measures of treatment effects (HIV-1 viral load and CD4 cell counts). Individuals in the study  
128 brought recent laboratory results, allowing us to verify their HIV status and know their current  
129 treatment and immune status. All medications were also brought to this visit to allow verification of  
130 current medication use. Persons who met entry criteria then completed the additional assessments as  
131 described in the next section.

### 132 **2.2.2 Acceptability**

133 We used several strategies to evaluate the feasibility and acceptability of the CCT with tDCS  
134 intervention to participants. We used a questionnaire based on the Technology Acceptance Model, or  
135 TAM [62, 63], the dimensions of which have received substantial support for use with digital health  
136 technologies [64]. The model specifies that users' perceptions of an application's ease of use and  
137 usefulness are related to their future intention to use the application. We hypothesized that if the  
138 intervention were viewed favorably by participants, their average rating on the Usefulness and Ease  
139 of Use scales of this questionnaire would be significantly different from the midpoint of the scale in a  
140 positive direction.

141 Another scale was developed based on a model balancing risks and benefits of a treatment was used  
142 to develop a questionnaire assessing users' perceptions of the balance between an intervention's risks  
143 and benefits [65, 66]. Participants were asked, for example, if they experienced benefits from the  
144 intervention and adverse effects from it. They were then asked to provide an overall judgment as to  
145 whether the benefits of the intervention outweighed its adverse effects.

### 146 **2.2.3 Cognitive measures**

147 In order to evaluate possible cognitive effects of the intervention more comprehensively, participants  
148 additional assessments after determination of their eligibility. Use of these measures allowed tests of  
149 the study's hypothesis that participants receiving the active interventions would display better  
150 performance than control participants in reaction time, attention, and psychomotor speed.

151 In order to evaluate intervention effects on participants' reaction time, they completed the California  
152 Computerized Assessment Package [67] (Miller, 2013). To further evaluate the effects of the  
153 intervention on executive functions, participants also completed the Stroop Color Word Test [68], the  
154 Iowa Gambling Task [69], and the Design Fluency subtest of the Delis-Kaplan Executive Function  
155 System [59](Delis et al., 2001). Finally, to assess whether the intervention had an impact on everyday  
156 functional performance, participants completed the Medication Management Test—Revised, a  
157 measure of the person's ability to understand and carry out medication-related tasks [70] and the  
158 University of San Diego Scales of Observed Performance [71], assessing their ability to perform  
159 everyday tasks such as making a medical appointment and paying a bill. Finally, in order to provide  
160 an estimate of participants' premorbid level of functioning, they completed the Wechsler Test of  
161 Adult Reading [72].

162

---

163 Insert Table 1 about here

164

#### 165 **2.2.4 Other self-report measures.**

166 The assessment battery also included the Patient's Assessment of Own Functioning or PAOF [73].  
167 This measure asks the individual to self-report their experience of mental problems in several  
168 domains such as language, perception, and memory. It has been used in other studies of HAND [74].  
169 We also used the Center for Epidemiological Studies Depression scale or CESD [75] to assess  
170 participants' symptoms of depression. All self-report assessments were completed using computer  
171 software that read questions aloud and enabled participants to record their responses by tapping on  
172 the computer screen.

#### 173 **2.2.5 Compensation**

174 After these initial assessments were done, individuals in the study were asked to return to begin the  
175 intervention. Participants received compensation for their involvement, US \$80 for the baseline and  
176 follow-up sessions, and \$40 for each intervention visit.

#### 177 **2.2.6 Computer-based cognitive training**

178 At the first training visit (after completion of baseline assessments), participants were assigned to  
179 intervention group using a computer-created randomization scheme. The scheme was generated via  
180 random numbers in a predetermined block (n = 3) randomization scheme. Participants were enrolled  
181 by the study coordinator (who was blind to treatment assignment) and assigned by the unblinded  
182 principal investigator who also conducted all training sessions.

183 First, procedures regarding the administration of tDCS and the use of the game controller (an Xbox  
184 game controller with USB interface to a Windows computer). The participant sat in front of and to  
185 the right of the researcher; the participant could not see the direct current device for tDCS or the  
186 researcher taking notes during training. For all participants, the anode electrode was located over the  
187 left dorsolateral prefrontal cortex (10-20 system F3) and the cathode over the right supraorbital area  
188 (FP2) [76]. Soterix EASYPads, doubled sponges with dimensions of 5 cm x 5 cm (Soterix Medical:  
189 New York) were used as electrodes. Approximately 7 cc of sterile saline was used to moisten them.  
190 They were positioned by the researcher and then fixed in place with a head band. Current for the  
191 tDCS intervention was supplied with an iontophoresis device (ActivaDose II; Gilroy, CA: Activatek).  
192 Flat rubberized carbon electrodes were inserted into the moistened sponges. Impedances were  
193 assessed before each session and kept below 20K ohms prior to stimulation.

194 We told people in the study that they might experience minor discomfort at the beginning of the  
195 session and that the experience might persist or fade away during the intervention [50]. We then  
196 asked the persons in the study to pay attention to the computer while the game was set up and the  
197 tDCS intervention was begun. Individuals in the active tDCS group received a current of 1.5 mA,  
198 ramping up over 30 s and continuing for 20 minutes. Individuals in the sham tDCS group and the  
199 control group received the ramping up current for 30 s which was then ramped down over 30 s.

200 The cognitive training intervention in this study was a commercially-available car racing game *GT*  
201 *Racing 2* (Gameloft SE: Paris, France). This game was chosen because it was easy for most persons  
202 and was positively reviewed by a large number of users. We inferred from these characteristics that  
203 the participants in the study would find the content tolerable and might even enjoy playing the game.  
204 The game includes a several different race courses and types of races to enhance player interest.  
205 Game play required that each participant complete each course before moving on to the next.

206 Everyone in the study randomized to CCT was able to complete at least the first four courses during  
207 six training sessions.

208 We encouraged participants to complete each gaming session at their desired pace, although the game  
209 imposed some restrictions on their progress. Players had to finish each race in one of the top three  
210 places, or navigate a course within a predetermined time, before moving on to the next course. We  
211 required as well that participants do each course a minimum of five times. Persons in the study  
212 completed six training sessions over a two-week period. After each intervention session, participants  
213 were asked to provide ratings of their thinking, their mood, and how much discomfort they had  
214 experienced during the intervention.

215 Assessments and intervention sessions were completed within three weeks from the baseline  
216 evaluation. After participants finished the sixth intervention session, they returned to complete  
217 cognitive and self-report assessment. Cognitive evaluations were completed by staff who did not  
218 know the participant's intervention group assignment. About 30 days after completing the  
219 intervention sessions and follow-up evaluations, persons in the study were asked to return to again  
220 complete assessments. All data were collected in the General Clinical Research Center at the Center  
221 for Collaborative Research on the campus of Nova Southeastern University beginning in January  
222 2018 and ending in November 2019. The study was concluded at the end of the period of funding  
223 support.

### 224 **2.3 Human subjects approval and trial registration**

225 Study procedures were approved by the Institutional Review Board of Nova Southeastern University  
226 (protocol number 2017-410). This study was registered on ClinicalTrials.gov (NCT03440840).

### 227 **2.4 Data Analyses**

228 Planned sample size was determined prior to beginning the study using the mixed effects model  
229 simulation routine in PASS 16 [77]. The power analysis showed that a final sample size of 90 (30 per  
230 treatment group) would have a power of 0.88 to detect interactions of group membership with time  
231 (number of evaluations) with a small effect size [78, 79].

232 Data analyses were completed in several steps. Preliminary analyses of data and descriptive statistics  
233 were obtained using SPSS version 26 (Armonk NY: IBM). Chi-square and one-way ANOVA tests  
234 evaluating the relations of participant ratings of the acceptability and feasibility of the intervention to  
235 group assignment were also completed in SPSS. Analyses of treatment effects were completed using  
236 R version 4.0.2 [80] package lme4 [81] for mixed effects models. Significance of model effects  
237 (interaction of treatment group assignment with time) was assessed using the likelihood ratio test  
238 [82]. We evaluated outcomes both through tests of statistical significance as well as approximations  
239 of effect size from  $\chi^2$  values from likelihood ratio tests and t values obtained in tests of between-  
240 group differences obtained using emmeans [83]. Effect sizes were converted to the more familiar d  
241 statistic using the package esc [84]. As a post-hoc assessment not included in the original study  
242 protocol the probability of finding the observed number of treatment effects in the hypothesized  
243 direction was evaluated using the exact binomial test in the package stats.

## 244 **3 Results**

245 The study's CONSORT diagram [85] is presented in Figure 1. Demographic, educational and  
246 baseline scores for cognitive and functional measures for participants by treatment group are

247 presented in Table 2. We screened 155 potential participants, and included 46 in the study. Reasons  
248 for excluding potential participants are listed in Figure 1. The most frequent reasons for exclusion  
249 were use of psychotropic medications, and a personal or family history of bipolar disorder. We thus  
250 were not able to include the full number of participants in the study as originally envisioned (planned  
251 N = 30 per group).

252

---

Insert Figure 1 about here

---

253

254

255

---

Insert Table 2 about here

---

256

257

258 We explored relations of relevant covariates (age, gender, education, immune status) to mental ability  
259 variables with standard measures of association (correlations). As several of these associations were  
260 substantial and likely to create confounding relations, they were included as covariates in mixed  
261 effects random intercept models. Outcomes assessed were changes in test scores across treatment  
262 groups before and after the study intervention.

### 263 **3.1 Acceptability to participants**

264 As hypothesized, participants rated the intervention significantly more positively than the midpoint  
265 of the Usefulness subscale of the TAM scale. The mean rating for all participants was 4.33 (SD =  
266 1.27; scale range 0 to 6), and this rating was significantly greater than the neutral midpoint ( $t [40] =$   
267  $6.71, p < 0.001$ ). We also found that they rated its ease of use positively with a mean rating of 5.04  
268 (SD = 0.95), ratings that were again significantly greater than the scale midpoint ( $t [43] = 5.04, p <$   
269  $0.001$ ). Ratings suggested that overall, they enjoyed the intervention (mean = 4.73; SD = 1.30) and  
270 would use it again if given the opportunity (mean = 4.62; SD = 1.25). Participants' ratings did not  
271 vary by treatment group (all  $ps > 0.35$ ).

272 On the scale which asked participants to assess the intervention's risks and benefits, participant  
273 ratings again suggested a positive evaluation, with a mean rating of 4.53 (SD = 1.20; scale range 0 to  
274 6) on the item "overall the good outweighs the bad" and a rating of 4.70 (SD = 1.01) on the item  
275 "overall satisfaction." Forty-three of 46 participants (93%) indicated they were satisfied with the  
276 intervention.

### 277 **3.2 Cognitive and functional outcomes**

278 Results of evaluations of study outcomes assessed as the interactions of intervention group across  
279 evaluations are available in Table 3.

280

---

Insert Table 3 about here

---

281

282

283 We found mixed evidence across cognitive domains to support the hypothesis that CCT with and  
284 without tDCS might result in improvements in cognitive functioning relative to control. For the Digit  
285 Span Forward subtest, the interaction of treatment group by time approached statistical significance  
286 and represented a large effect size. The difference between active tDCS and the control group (Figure  
287 2) also approached statistical significance ( $t [61.3] = 2.19, p = 0.08; d = 0.79$ ). Other subtests  
288 hypothesized to assess attention showed similar positive but nonsignificant interactions.

289

---

Insert Figure 2 about here

---

290

291

292 Results did not support the hypothesis that persons receiving CCT with or without tDCS would show  
293 improved reaction time. Although the observed interactions were in the hypothesized direction, they  
294 were not significant and represented at best a very small effect size.

295 Results again provided limited support for the hypothesis that CCT with tDCS might result in  
296 improved psychomotor speed compared to control (Figure 3). Although the overall interaction of  
297 group by time was not significant for Trails B, the comparison of the active treatment group to  
298 control approached significance ( $t [67.2] = 2.37, p = 0.053; d = 0.85$ ), a difference that became  
299 significant at second follow-up ( $t [67.2] = 3.03, p = 0.01; d = 1.09$ ).

300

---

Insert Figure 3 about here

---

301

302

303

304 We found support for the hypothesis of improvement in psychomotor speed with a significant  
305 interaction of group by time for the WAIS-IV Coding subtest, although examination of the  
306 interaction plot suggests the effect was primarily due to the performance of persons in the CCT with  
307 sham tDCS (Figure 4). The between group difference from CCT + sham was not significant at  
308 immediate follow-up ( $t [45.6] = 1.02, p = 0.57; d = 0.37$ ) but approached significance at one-month  
309 follow-up ( $t [45.6] = 2.21, p = 0.08; d = 0.79$ ).

310

---

Insert Figure 4 about here

---

311

312

313 This pattern was again found in results for the HVLt total score, with a significant interaction of  
314 group by time resulting from differential improvement in both treatment groups, with significant  
315 difference between the CCT + active tDCS group and control at immediate follow-up ( $t [69.6] =$   
316  $2.51, p = 0.04; d = 0.90$ ) and a substantial but no longer significant difference at one-month follow-  
317 up ( $t [69.6] = 2.05, p = 0.11; d = 0.73$ ; Figure 5).

318



319

320

---

Insert Figure 5 about here

---

321

322 Although we did not pose specific hypotheses for the effects of CCT with or without tDCS on  
323 executive function for this study, in exploratory analyses we evaluated the intervention's effects on  
324 this domain with several measures. A significant interaction of group by time was found for the  
325 Stroop with a large effect size, but as with several other measures, the finding was related to  
326 substantial improvement in the CCT with sham stimulation group. Other interactions were again  
327 positive but nonsignificant, with effect sizes in the moderate range.

328 As with executive function, we did not propose specific hypotheses for the two functional measures  
329 included in the assessments, but explored the intervention's effect on them. Results suggest a  
330 moderate but nonsignificant effect size for the MMT with a negligible effect size for the UPSA.

331 Given the large number of outcomes and our use of effect sizes to evaluate treatment effects, in an  
332 unplanned post-hoc analysis, we evaluated the overall impact of the study intervention based on the  
333 number of effect sizes for cognitive variables that were in the hypothesized direction (showing an  
334 interaction of group by time favoring one of the active treatment groups). The average effect size was  
335 0.52, with 17 effects equal to or greater than 0.16, a small effect size [78]. The probability of this  
336 outcome compared to chance (equal distribution of positive effects across all groups) was  
337 significantly different ( $p = 0.04$ ). It is thus improbable that the observed effects of the intervention  
338 were only due to chance. It should be acknowledged, that this analysis included positive effects for  
339 either treatment group and did not support the original hypothesis that the effects of CCT with active  
340 tDCS would be superior to CCT with sham tDCS.

### 341 **3.2.1 Self-report outcomes**

342 Evaluations of treatment by time interactions of participant self-report on the PAOF subscales  
343 (PAOF Memory,  $\chi^2 [4] = 1.86$ ,  $p = 0.76$ ,  $d = 0.41$ ; Cognition subscale,  $\chi^2 [4] = 0.37$ ,  $p = 0.98$ ,  $d =$   
344  $0.18$ ) and the CESD ( $\chi^2 [4] = 3.38$ ,  $p = 0.50$ ,  $d = 0.56$ ) did not result suggest substantial between-  
345 group differences in response to the intervention. Examination of the interaction plots for the PAOF  
346 subscales (not presented) showed that mean scores for all three groups improved to a similar extent  
347 over the three evaluations. Participants reported similar levels of depression (CESD) across groups  
348 and evaluations, except participants in the active treatment group reported better mood at the one-  
349 month follow-up evaluation. Although the test of between groups differences were not significant,  
350 the within-group change from the immediate follow-up to the one-month follow-up for the CCT with  
351 active tDCS group approached significance and represented a large effect size ( $t [78.2] = 2.17$ ,  $p =$   
352  $0.08$ ,  $d = 0.78$ ).

353 Evaluation of participant ratings of how well they could think and remember resulted in an  
354 interaction that again approached statistical significance ( $\chi^2 [10] = 17.47$ ,  $p = 0.06$ ,  $d = 1.59$ ).  
355 Examination of the interaction plot (Figure 6) suggests that persons in the active treatment group  
356 reported better ability to think over the final three training sessions, although between-group  
357 differences were not statistically significant ( $t [106.8] = 1.57$ ,  $p = 0.26$ ,  $d = 0.56$ ).

358

359

360

---

Insert Figure 6 about here

---

361

## 362 4 Discussion

363 This study's goals were to assess the acceptability of CCT using a racing game to persons 50 years of  
364 age and older with HAND. The impact of adding tDCS to CCT was also evaluated. As we had a  
365 smaller than expected sample, we assessed outcomes not only through tests of statistical significance  
366 but also through calculation of effect sizes. Results showed that the majority of participants had  
367 positive views of the intervention and believed its benefits outweighed any risks. Ratings of its  
368 usefulness and usability were positive.

369 Our results clearly show that participants found the intervention acceptable. The majority of ratings  
370 on factors such as usefulness and ease of use were positive, and nearly all participants indicated that  
371 they felt the benefits of the intervention outweighed any drawbacks. Further exploration of ways to  
372 make the intervention even more positive for persons with HAND appear warranted.

373 Assessment of mental abilities before and after training suggested that the intervention had a positive  
374 effect on learning, memory, and motor speed compared to control. Although only a few outcomes  
375 were statistically significant or approached it, those which were significant were associated with  
376 large effect sizes. Outcomes with moderate or smaller effect sizes may thus have been nonsignificant  
377 due to low power related to the sample size rather than a lack of effect. A post-hoc evaluation of the  
378 probability of arriving at the observed set of effect sizes by chance suggested that our findings were  
379 not due to chance. Further, effect sizes obtained in this study are similar to those reported by other  
380 researchers, including in a meta-analysis of studies with older adults [86].

381 Consistent with other research, the combination of cognitive training and anodal tDCS at the left  
382 dorsolateral prefrontal cortex was associated with improvement in attention as measured by digit  
383 span [37, 87, 88]. Contrary to our hypothesis, however, there was no evidence of a substantial impact  
384 of the intervention on reaction time. Others have reported that tDCS may have a facilitating effect on  
385 reaction time with anodal stimulation over primary motor cortex, but Molero-Chamizo et al. found  
386 that the effect was time dependent [89]. Others have also failed to find an effect of tDCS [90, 91] on  
387 reaction time. Our hypothesis of an effect on reaction time was based primarily on the nature of the  
388 training task (a fast-paced computer game), but neither statistical tests nor inspection of mean plots  
389 by groups (not presented) suggested an effect for either of the active treatment groups.

390 We found more substantial improvements in measures of psychomotor speed, including a significant  
391 interaction of group by time for the WAIS-IV Coding subtest. Although the overall interaction for  
392 Trails B was not significant, inspection of group mean plots was consistent with relatively greater  
393 improvement on this measure for the two active treatment groups, and post-hoc between groups tests  
394 showed a significant difference between the control and CCT + active tDCS group after treatment  
395 while none was found at baseline.

396 A significant effect was also found for the Stroop Color-Word Test, a measure often interpreted as  
397 assessing a person's ability to inhibit well-learned responses [92]. Others have observed a positive  
398 effect of tDCS on the Stroop task [93-95], while Frings et al. found that cathodal stimulation of the

399 left DLPFC disrupted Stroop performance [96], with the negative effect of cathodal vs anodal  
400 stimulation expected.

401 We found limited support for the impact of the intervention on functional measures, with a moderate  
402 effect size but nonsignificant results for the Medication Management Test but no evidence of an  
403 effect on the UPSA. This is similar results reported by Vance et al. [97] who found limited effects of  
404 cognitive training on various measures of everyday function.

405 Self-report measures of mood or subjective cognitive functioning did not differ between groups, with  
406 one exception. The failure to find group differences may have been related to self-reported  
407 improvements across all groups, including the control. The one exception were self-reports of how  
408 well the participant perceived their thinking and memory, for which the CCT + active tDCS group  
409 gave substantially more positive reports over the last several sessions of the intervention.

410 The finding of possible treatment effects later during the training period suggests that the  
411 intervention's effects may have continued after training ended, with continuing improvements at one-  
412 month follow-up in psychomotor speed (Trail Making Test, Part B; Figure 3) and verbal learning  
413 (Hopkins Verbal Learning Test; Figure 5). We also found an improvement in depression self-report  
414 (Center for Epidemiological Studies – Depression) at one-month follow-up. This possibly delayed  
415 effect of tDCS on mood was also reported by Li [98]. Given the evidence for improvement during the  
416 second week of training, it is possible that a more intensive and longer intervention might have  
417 resulted in greater effects. This possibility should be explored in future studies.

418 Strengths of the study include the single-blind sham-controlled design, which was effective in our  
419 pilot study as it has been in other studies [99]. We collected all data using a staff member who did  
420 not know the participant's intervention assignment or by way of a computer. These measures reduced  
421 the likelihood of bias in outcomes due to experimenter effects. The characteristics of participants  
422 (age, gender, education level, cognitive function) made them similar to other persons who might have  
423 HAND and be able to benefit from the intervention. Another strength is the clear characterization of  
424 study participants with respect to concurrent medication use, although this in turn limited our ability  
425 to recruit participants.

426 This study's limitations include the smaller than planned sample size. In spite of intensive recruiting  
427 efforts in the local community, including newspaper and online advertising, multiple contacts with  
428 community organizations and local infectious disease practitioners, and contacts with participants in  
429 previous studies we were not able to recruit the planned number of participants for the study. As  
430 shown in Figure 1, we were able to contact a number of potential participants that might have been  
431 adequate for planned sample size for the study, but exclusion due to validity concerns related to  
432 psychotropic medication use and safety concerns related to history of bipolar disorder, a large  
433 number of potential participants were not eligible. This limitation in turn may have affected the  
434 ability to test the statistical significance of outcomes, although in several cases when we found large  
435 effect sizes, we also found statistically significant results. Generalizing our results based only on  
436 observed effect sizes is a limitation. Finally, it should be acknowledged that while we found a  
437 number of positive effects on cognitive measures in the two CCT groups, the original hypothesis that  
438 CCT with active tDCS would be superior to CCT with sham tDCS was not supported.

439 Another limitation is that this study did not employ a double-blind controlled design, raising the  
440 possibility of bias caused by the investigators.

441 As noted above, we did several things to reduce the possibility of effects related to the unblinded  
442 experimenter. These included positioning the investigator and the tDCS device out of sight of the  
443 participant during stimulation, providing neutral suggestions about what the participants might  
444 experience during stimulation, and collecting most self-report data via computer assisted self-  
445 interview with the investigators out of the room. All baseline and follow-up assessments were  
446 conducted by an assessor blind to the participant's treatment assignment or by way of a computer  
447 without the presence of a researcher. Thus, while we took a number of steps to reduce possible bias  
448 in the research design, they did not eliminate it.

449 HIV-related mental ability problems have implications for the functional status and quality of life for  
450 older persons with HAND. Our results, though limited, demonstrate the possibility that CCT with or  
451 without tDCS may have a positive impact on cognitive function. We found evidence of a moderate  
452 though nonsignificant effect of the intervention on a test of medication taking, a critically important  
453 skill for persons with HIV infection.

454 Future research should focus on continuing to explore the potential efficacy of CCT and tDCS with  
455 this population. A more detailed exploration of factors such as intensity and duration of stimulation  
456 and length and frequency of training sessions as well as the optimal timing of follow-up assessments  
457 may yield more effective treatment protocols with greater impacts on participants' functional status.

## 458 **5 Conflict of Interest**

459 The authors declare that they have no known competing financial interests or personal relationships  
460 that could have appeared to influence the work reported in this paper.

## 461 **6 Author Contributions**

462 RLO designed the study, obtained external funding, carried out the interventions, and wrote the draft  
463 of the manuscript. JK wrote a portion of the manuscript and reviewed the complete manuscript.  
464

## 465 **7 Funding**

466 This work was supported by a grant from the US National Institutes on Aging to Dr. Ownby (grant  
467 R21AG056256).

468

469

470

## References

- 471  
472
- 473 1. Thames AD, Arentoft A, Rivera-Mindt M, Hinkin CH. Functional disability in medication  
474 management and driving among individuals with HIV: a 1-year follow-up study. *J Clin Exp*  
475 *Neuropsychol.* 2013;35(1):49-58.
  - 476 2. Thames AD, Becker BW, Marcotte TD, Hines LJ, Foley JM, Ramezani A, et al. Depression,  
477 cognition, and self-appraisal of functional abilities in HIV: An examination of subjective appraisal  
478 aersus objective performance. *The Clinical Neuropsychologist.* 2011;25(2):224-43.
  - 479 3. Thames AD, Kim MS, Becker BW, Foley JM, Hines LJ, Singer EJ, et al. Medication and  
480 finance management among HIV-infected adults: The impact of age and cognition. *Journal of*  
481 *Clinical and Experimental Neuropsychology.* 2011;33(2):200-9.
  - 482 4. Hinkin CH, Castellon SA, Durvasula RS, Hardy DJ, Lam MN, Mason KI, et al. Medication  
483 adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. *Neurology.*  
484 2002;59(12):1944-50.
  - 485 5. Hinkin CH, Hardy DJ, Mason KI, Castellon SA, Durvasula RS, Lam MN, et al. Medication  
486 adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. *AIDS.*  
487 2004;18 Suppl 1:S19-25.
  - 488 6. Degroote S, Vogelaers D, Vandijck DM. What determines health-related quality of life  
489 among people living with HIV: an updated review of the literature. *Arch Public Health.*  
490 2014;72(1):40.
  - 491 7. Degroote S, Vogelaers DP, Vermeir P, Mariman A, De RA, Van Der Gucht B, et al. Socio-  
492 economic, behavioural, (neuro)psychological and clinical determinants of HRQoL in people living  
493 with HIV in Belgium: a pilot study. *J Int AIDS Soc.* 2013;16:18643.
  - 494 8. Moore RC, Fazeli PL, Jeste DV, Moore DJ, Grant I, Woods SP. Successful cognitive aging  
495 and health-related quality of life in younger and older adults infected with HIV. *AIDS Behav.*  
496 2014;18(6):1186-97.
  - 497 9. Tozzi V, Balestra P, Galgani S, Murri R, Bellagamba R, Narciso P, et al. Neurocognitive  
498 performance and quality of life in patients with HIV infection. *AIDS Res Hum Retroviruses.*  
499 2003;19(8):643-52.
  - 500 10. Valcour V, Shikuma C, Shiramizu B, Watters M, Poff P, Selnes O, et al. Higher frequency of  
501 dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. *Neurology.*  
502 2004;63(5):822-7.
  - 503 11. Wendelken LA, Valcour V. Impact of HIV and aging on neuropsychological function. *J*  
504 *Neurovirol.* 2012;18(4):256-63.
  - 505 12. Hinkin CH, Castellon SA, Hardy DJ, Farinpour R, Newton T, Singer E. Methylphenidate  
506 improves HIV-1-associated cognitive slowing. *J Neuropsychiatry Clin Neurosci.* 2001;13(2):248-54.
  - 507 13. Decloedt EH, Freeman C, Howells F, Casson-Crook M, Lesosky M, Koutsilieris E, et al.  
508 Moderate to severe HIV-associated neurocognitive impairment: A randomized placebo-controlled  
509 trial of lithium. *Medicine (Baltimore).* 2016;95(46):e5401.
  - 510 14. Nakasujja N, Miyahara S, Evans S, Lee A, Musisi S, Katabira E, et al. Randomized trial of  
511 minocycline in the treatment of HIV-associated cognitive impairment. *Neurology.* 2013;80(2):196-  
512 202.

- 513 15. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research  
514 nosology for HIV-associated neurocognitive disorders. *Neurology*. 2007;69(18):1789-99.
- 515 16. Sacktor N, Miyahara S, Deng L, Evans S, Schifitto G, Cohen BA, et al. Minocycline  
516 treatment for HIV-associated cognitive impairment: results from a randomized trial. *Neurology*.  
517 2011;77(12):1135-42.
- 518 17. Schifitto G, Yiannoutsos CT, Ernst T, Navia BA, Nath A, Sacktor N, et al. Selegiline and  
519 oxidative stress in HIV-associated cognitive impairment. *Neurology*. 2009;73(23):1975-81.
- 520 18. Schifitto G, Zhang J, Evans SR, Sacktor N, Simpson D, Millar LL, et al. A multicenter trial of  
521 selegiline transdermal system for HIV-associated cognitive impairment. *Neurology*.  
522 2007;69(13):1314-21.
- 523 19. Cody SL, Vance DE. The neurobiology of HIV and its impact on cognitive reserve: A review  
524 of cognitive interventions for an aging population. *Neurobiol Dis*. 2016;92(Pt B):144-56.
- 525 20. Vance DE, Fazeli PL, Cheatwood J, Nicholson WC, Morrison SA, Moneyham LD.  
526 Computerized cognitive training for the neurocognitive complications of HIV infection: A systematic  
527 review. *J Assoc Nurses AIDS Care*. 2019;30(1):51-72.
- 528 21. Vance DE, Fazeli PL, Ross LA, Wadley VG, Ball KK. Speed of processing training with  
529 middle-age and older adults with HIV: a pilot study. *J Assoc Nurses AIDS Care*. 2012;23(6):500-10.
- 530 22. Bonnechère B, Langley C, Sahakian BJ. The use of commercial computerised cognitive  
531 games in older adults: a meta-analysis. *Scientific Reports*. 2020;10(1):15276.
- 532 23. Zelinski EM, Reyes R. Cognitive benefits of computer games for older adults.  
533 *Gerontechnology*. 2009;8(4):220-35.
- 534 24. Green CS, Seitz AR. The impacts of video games on cognition (and how the government can  
535 guide the industry). *Policy Insights from the Behavioral and Brain Sciences*. 2015;2(1):101-10.
- 536 25. Wu S, Spence I. Playing shooter and driving videogames improves top-down guidance in  
537 visual search. *Atten Percept Psychophys*. 2013;75(4):673-86.
- 538 26. Anguera JA, Boccanfuso J, Rintoul JL, Al-Hashimi O, Faraji F, Janowich J, et al. Video game  
539 training enhances cognitive control in older adults. *Nature*. 2013;501(7465):97-101.
- 540 27. Basak C, Boot WR, Voss MW, Kramer AF. Can training in a real-time strategy video game  
541 attenuate cognitive decline in older adults? *Psychol Aging*. 2008;23(4):765-77.
- 542 28. Bavelier D, Green CS. The brain-boosting power of video games. *Sci Am*. 2016;315(1):26-  
543 31.
- 544 29. Belchior P, Marsiske M, Leite WL, Yam A, Thomas K, Mann W. Older adults' engagement  
545 during an intervention involving off-the-shelf videogame. *Games Health J*. 2016;5(3):151-6.
- 546 30. Belchior P, Marsiske M, Sisco S, Yam A, Mann W. Older adults' engagement with a video  
547 game training program. *Act Adapt Aging*. 2012;36(4):269-79.
- 548 31. Cardoso-Leite P, Bavelier D. Video game play, attention, and learning: how to shape the  
549 development of attention and influence learning? *Curr Opin Neurol*. 2014;27(2):185-91.
- 550 32. Coffman BA, Trumbo MC, Clark VP. Enhancement of object detection with transcranial  
551 direct current stimulation is associated with increased attention. *BMC Neurosci*. 2012;13:108.

- 552 33. Lawrence BJ, Gasson N, Bucks RS, Troeung L, Loftus AM. Cognitive training and  
553 noninvasive brain stimulation for cognition in Parkinson's disease: A meta-analysis. *Neurorehabil*  
554 *Neural Repair*. 2017;31(7):597-608.
- 555 34. Lawrence BJ, Gasson N, Johnson AR, Booth L, Loftus AM. Cognitive training and  
556 transcranial direct current stimulation for mild cognitive impairment in Parkinson's Disease: A  
557 randomized controlled trial. *Parkinson's Disease*. 2018;2018:4318475.
- 558 35. Leshikar ED, Leach RC, McCurdy MP, Trumbo MC, Sklenar AM, Frankenstein AN, et al.  
559 Transcranial direct current stimulation of dorsolateral prefrontal cortex during encoding improves  
560 recall but not recognition memory. *Neuropsychologia*. 2017;106:390-7.
- 561 36. Martin DM, Liu R, Alonzo A, Green M, Loo CK. Use of transcranial direct current  
562 stimulation (tDCS) to enhance cognitive training: effect of timing of stimulation. *Exp Brain Res*.  
563 2014;232(10):3345-51.
- 564 37. Martin DM, Liu R, Alonzo A, Green M, Player MJ, Sachdev P, et al. Can transcranial direct  
565 current stimulation enhance outcomes from cognitive training? A randomized controlled trial in  
566 healthy participants. *Int J Neuropsychopharmacol*. 2013;16(9):1927-36.
- 567 38. Trumbo MC, Matzen LE, Coffman BA, Hunter MA, Jones AP, Robinson CSH, et al.  
568 Enhanced working memory performance via transcranial direct current stimulation: The possibility of  
569 near and far transfer. *Neuropsychologia*. 2016;93(Pt A):85-96.
- 570 39. Cerruti C, Schlaug G. Anodal transcranial direct current stimulation of the prefrontal cortex  
571 enhances complex verbal associative thought. *J Cogn Neurosci*. 2009;21(10):1980-7.
- 572 40. Fregni F, Boggio PS, Nitsche M, Berman F, Antal A, Feredoes E, et al. Anodal transcranial  
573 direct current stimulation of prefrontal cortex enhances working memory. *Exp Brain Res*.  
574 2005;166(1):23-30.
- 575 41. Heimrath K, Sandmann P, Becke A, Muller NG, Zaehle T. Behavioral and  
576 electrophysiological effects of transcranial direct current stimulation of the parietal cortex in a visuo-  
577 spatial working memory task. *Front Psychiatry*. 2012;3:56.
- 578 42. Zaehle T, Sandmann P, Thorne JD, Jancke L, Herrmann CS. Transcranial direct current  
579 stimulation of the prefrontal cortex modulates working memory performance: combined behavioural  
580 and electrophysiological evidence. *BMC Neurosci*. 2011;12:2.
- 581 43. Clark VP, Coffman BA, Mayer AR, Weisend MP, Lane TD, Calhoun VD, et al. TDCS  
582 guided using fMRI significantly accelerates learning to identify concealed objects. *Neuroimage*.  
583 2012;59(1):117-28.
- 584 44. Floel A, Suttorp W, Kohl O, Kurten J, Lohmann H, Breitenstein C, et al. Non-invasive brain  
585 stimulation improves object-location learning in the elderly. *Neurobiol Aging*. 2012;33(8):1682-9.
- 586 45. Fritsch B, Reis J, Martinowich K, Schambra HM, Ji Y, Cohen LG. Direct current stimulation  
587 promotes BDNF-dependent synaptic plasticity: potential implications for motor learning. *Neuron*.  
588 2010;66.
- 589 46. Avdoshina V, Bachis A, Mocchetti I. Synaptic dysfunction in human immunodeficiency virus  
590 type-1-positive subjects: inflammation or impaired neuronal plasticity? *J Intern Med*.  
591 2013;273(5):454-65.
- 592 47. Bachis A, Avdoshina V, Zecca L, Parsadanian M, Mocchetti I. Human immunodeficiency  
593 virus type 1 alters brain-derived neurotrophic factor processing in neurons. *J Neurosci*.  
594 2012;32(28):9477-84.

- 595 48. Buchman AS, Yu L, Boyle PA, Schneider JA, De Jager PL, Bennett DA. Higher brain BDNF  
596 gene expression is associated with slower cognitive decline in older adults. *Neurology*.  
597 2016;86(8):735-41.
- 598 49. Ownby RL, Acevedo A. A pilot study of cognitive training with and without transcranial  
599 direct current stimulation (tDCS) to improve cognition in older persons with HIV-related cognitive  
600 impairment. *Neuropsychiatr Dis Treat*. 2016;12:2745-54.
- 601 50. Brunoni AR, Valiengo L, Baccaro A, Zanao TA, de Oliveira JF, Goulart A, et al. The  
602 sertraline vs. electrical current therapy for treating depression clinical study: results from a factorial,  
603 randomized, controlled trial. *JAMA Psychiatry*. 2013;70(4):383-91.
- 604 51. Galvez V, Alonzo A, Martin D, Mitchell PB, Sachdev P, Loo CK. Hypomania induction in a  
605 patient with bipolar II disorder by transcranial direct current stimulation (tDCS). *J ECT*.  
606 2011;27(3):256-8.
- 607 52. McLaren ME, Nissim NR, Woods AJ. The effects of medication use in transcranial direct  
608 current stimulation: A brief review. *Brain Stimulation: Basic, Translational, and Clinical Research in*  
609 *Neuromodulation*. 2018;11(1):52-8.
- 610 53. Medeiros LF, de Souza IC, Vidor LP, de Souza A, Deitos A, Volz MS, et al. Neurobiological  
611 effects of transcranial direct current stimulation: A review. *Frontiers in Psychiatry*. 2012;3(110).
- 612 54. European AIDS Clinical Society. Guidelines 8.0. Brussels: European AIDS Clinical Society;  
613 2015 2015.
- 614 55. Woods SP, Moore DJ, Weber E, Grant I. Cognitive neuropsychology of HIV-associated  
615 neurocognitive disorders. *Neuropsychol Rev*. 2009;19(2):152-68.
- 616 56. Wechsler D. Manual for the Wechsler Adult Intelligence Scale--IV. San Antonio TX: Pearson  
617 Assessment; 2008.
- 618 57. Lafayette Instrument Company. Grooved Pegboard Test user instructions. Lafayette IN:  
619 Lafayette Instrument Company; 2002.
- 620 58. Lezak M. Neuropsychological assessment, Fifth edition. New York: Oxford; 2004.
- 621 59. Delis DC, Kaplan E, Kramer JH. Delis-Kaplan Executive Function System (D-KEFS). San  
622 Antonio TX: The Psychological Corporation; 2001 2001.
- 623 60. Brandt J, Benedict RH. Hopkins Verbal Learning Test--Revised: Professional manual.  
624 Odessa FL: Psychological Assessment Resources; 2001.
- 625 61. Benedict RB, Schretlen D, Groninger L, Dobraski M, Sphritz B. Revision of the Brief  
626 Visuospatial Memory Test: Studies of normal performance, reliability and validity. *Psychological*  
627 *Assessment*. 1996;8:145-53.
- 628 62. Venkatesh V, Bala H. Technology Acceptance Model 3 and a research agenda on  
629 interventions. *Decision Sciences*. 2008;39(2):273-315.
- 630 63. Venkatesh V, Morris MG, Davis GB, Davis FD. User acceptance of information technology:  
631 Toward a unified view. *MIS Quarterly*. 2003;27(3):425-78.
- 632 64. Binyamin SS, Zafar BA. Proposing a mobile apps acceptance model for users in the health  
633 area: A systematic literature review and meta-analysis. *Health Informatics Journal*.  
634 2021;27(1):1460458220976737.



- 635 65. Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. Hierarchical construct validity of the  
636 treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy  
637 consumers. *Value Health*. 2005;8 Suppl 1:S9-S24.
- 638 66. Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, et al. Validation of a  
639 general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication  
640 (TSQM), using a national panel study of chronic disease. *Health Qual Life Outcomes*. 2004;2:12.
- 641 67. Miller EN. *California Computerized Assessment Package Manual*, 2nd ed. Palm Springs, CA:  
642 Eric N. Miller; 2013 2013.
- 643 68. Golden CJ. *Stroop Color Word Test Manual*. Chicago: Stoelting; 1978.
- 644 69. Bechara A, Damasio H, Tranel D, Damasio AR. The Iowa Gambling Task and the somatic  
645 marker hypothesis: some questions and answers. *Trends Cogn Sci*. 2005;9(4):159-62; discussion 62-  
646 4.
- 647 70. Albert SM, Weber CM, Todak G, Polanco C, Clouse R, McElhiney M, et al. An observed  
648 performance test of medication management ability in HIV: Relation to neuropsychological status  
649 and medication adherence outcomes. *AIDS and Behavior*. 1999;3(2):121-8.
- 650 71. Patterson TL, Goldman S, McKibbin CL, Hughs T, Jeste DV. UCSD Performance-Based  
651 Skills Assessment: development of a new measure of everyday functioning for severely mentally ill  
652 adults. *Schizophr Bull*. 2001;27(2):235-45.
- 653 72. Wechsler D. *The Wechsler Test of Adult Reading*. San Antonio: The Psychological  
654 Corporation; 2001 2001.
- 655 73. Chelune GJ, Heaton RK, Lehman RAW. Neuropsychological and personality correlates of  
656 patients' complaints of disability. In: Goldstein G, Tarter RE, editors. *Advances in clinical  
657 neuropsychology*, Vol 3. New York: Springer; 1986. p. 95-126.
- 658 74. Rourke SB, Halman MH, Bassel C. Neurocognitive complaints in HIV-infection and their  
659 relationship to depressive symptoms and neuropsychological functioning. *J Clin Exp Neuropsychol*.  
660 1999;21(6):737-56.
- 661 75. Radloff LS. The CES-D scale: A self-report depression scale for research in the general  
662 population. *Applied Psychological Measurement*. 1977;1:385-481.
- 663 76. Acharya JN, Hani A, Cheek J, Thirumala P, Tsuchida TN. American Clinical  
664 Neurophysiology Society guideline 2: Guidelines for standard electrode position nomenclature. *J  
665 Clin Neurophysiol*. 2016;33(4):308-11.
- 666 77. Hintze J. *PASS 16*. Kaysville UT: NCSS, LLC.; 2018 2011.
- 667 78. Brydges CR. Effect size guidelines, sample size calculations, and statistical power in  
668 gerontology. *Innovation in Aging*. 2019;3(4).
- 669 79. Cohen J. *Statistical power analysis for the behavioral sciences* (2nd ed.). New York:  
670 Routledge; 1988.
- 671 80. R Core Team. *R: A language and environment for statistical computing*. Vienna, Austria: R  
672 foundation for statistical computing; 2020.
- 673 81. Bates D, Maechler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4.  
674 *Journal of Statistical Software*. 2015;67(1):1-48.

- 675 82. Kuznetsova A, Brockhoff PB, Christensen RHB. lmerTest package: Tests in linear mixed  
676 effects models. *Journal of Statistical Software*. 2017;82:1-26.
- 677 83. Lenth R. Estimated marginal means, aka least-squares means. 2020. p. R package version  
678 1.5.0.
- 679 84. Ludecke D. Effect size computation for meta analysis. Vienna, Austria: R Core Team; 2019.
- 680 85. Moher D. CONSORT: an evolving tool to help improve the quality of reports of randomized  
681 controlled trials. *Consolidated Standards of Reporting Trials*. *Jama*. 1998;279(18):1489-91.
- 682 86. Indahlastari A, Hardcastle C, Albizu A, Alvarez-Alvarado S, Boutzoukas EM, Evangelista  
683 ND, et al. A systematic review and meta-analysis of transcranial direct current stimulation to  
684 remediate age-related cognitive decline in healthy older adults. *Neuropsychiatr Dis Treat*.  
685 2021;17:971-90.
- 686 87. Park S-H, Seo J-H, Kim Y-H, Ko M-H. Long-term effects of transcranial direct current  
687 stimulation combined with computer-assisted cognitive training in healthy older adults. *Neuroreport*.  
688 2014;25.
- 689 88. Santos VSdSd, Zortea M, Alves RL, Naziazeno CCdS, Saldanha JS, Carvalho SdCRd, et al.  
690 Cognitive effects of transcranial direct current stimulation combined with working memory training  
691 in fibromyalgia: a randomized clinical trial. *Scientific Reports*. 2018;8(1):12477.
- 692 89. Molero-Chamizo A, Alameda Bailén JR, Garrido Béjar T, García López M, Jaén Rodríguez I,  
693 Gutiérrez Lérica C, et al. Poststimulation time interval-dependent effects of motor cortex anodal  
694 tDCS on reaction-time task performance. *Cogn Affect Behav Neurosci*. 2018;18(1):167-75.
- 695 90. Coppens MJM, Staring WHA, Nonnekens J, Geurts ACH, Weerdesteyn V. Offline effects of  
696 transcranial direct current stimulation on reaction times of lower extremity movements in people after  
697 stroke: a pilot cross-over study. *Journal of NeuroEngineering and Rehabilitation*. 2019;16(1):136.
- 698 91. Seidel O, Ragert P. Effects of transcranial direct current stimulation of primary motor cortex  
699 on reaction time and tapping performance: A comparison between athletes and non-athletes. *Frontiers*  
700 *in Human Neuroscience*. 2019;13(103).
- 701 92. Scarpina F, Tagini S. The Stroop Color and Word Test. *Frontiers in Psychology*. 2017;8(557).
- 702 93. Loftus AM, Yalcin O, Baughman FD, Vanman EJ, Hagger MS. The impact of transcranial  
703 direct current stimulation on inhibitory control in young adults. *Brain Behav*. 2015;5(5):e00332.
- 704 94. Lu H, Gong Y, Huang P, Zhang Y, Guo Z, Zhu X, et al. Effect of repeated anodal HD-tDCS  
705 on executive functions: Evidence from a pilot and single-blinded fNIRS study. *Frontiers in Human*  
706 *Neuroscience*. 2021;14(609).
- 707 95. Perrotta D, Bianco V, Berchicci M, Quinzi F, Perri RL. Anodal tDCS over the dorsolateral  
708 prefrontal cortex reduces Stroop errors. A comparison of different tasks and designs. *Behavioural*  
709 *Brain Research*. 2021;405:113215.
- 710 96. Frings C, Brinkmann T, Friehs MA, van Lipzig T. Single session tDCS over the left DLPFC  
711 disrupts interference processing. *Brain Cogn*. 2018;120:1-7.
- 712 97. Vance DE, Fazeli P, Azuero A, Frank JS, Wadley VG, Raper JL, et al. Can individualized-  
713 targeted computerized cognitive training improve everyday functioning in adults with HIV-  
714 associated neurocognitive disorder? *Applied Neuropsychology: Adult*. 2021:1-12.

- 715 98. Li M-S, Du X-D, Chu H-C, Liao Y-Y, Pan W, Li Z, et al. Delayed effect of bifrontal  
716 transcranial direct current stimulation in patients with treatment-resistant depression: a pilot study.  
717 BMC Psychiatry. 2019;19(1):180.
- 718 99. Woods AJ, Antal A, Bikson M, Boggio PS, Brunoni AR, Celnik P, et al. A technical guide to  
719 tDCS, and related non-invasive brain stimulation tools. Clin Neurophysiol. 2016;127(2):1031-48.

720

721

722 **8 Figure Captions**

723 Figure 1. CONSORT diagram

724 Figure 2. WAIS-IV Digit Span Forward subtest score by Group and Time

725 Figure 3. Trail Making Test, Part B by Group and Time

726 Figure 3 footnote: Lower scores indicate better performance

727 Figure 4. WAIS-IV Coding subtest scores by Group and Time

728 Figure 5. Hopkins Verbal Learning Test total score, Part B by Group and Time

729 Figure 6. Participants' Self-rated Thinking and Memory by Group and Training Session

730

Table 1. Cognitive and Functional Measures Used

Domain	Measure
Reaction Time	<i>California Computerized Assessment Package (CalCap)</i> [66]
Attention	* <i>Wechsler Adult Intelligence Scale, 4<sup>th</sup> Ed.</i> , Digit Span subtest [99]
	<i>Wechsler Memory Scale, 4<sup>th</sup> ed.</i> , Symbol Span subtest [101]
Psychomotor Speed	* <i>Wechsler Adult Intelligence Scale, 4<sup>th</sup> ed.</i> , Coding subtest [100]
	*Trail Making Test, Part A [78]
	*Grooved Pegboard [51]
Premorbid function	Wechsler Test of Adult Reading [98]
Executive function	*Trail Making Test, Part B [78]
	*Verbal and Design Fluency from D-KEFS [36]
	Stroop Color Word Test [42]
	Iowa Gambling Task [12]
Learning and Memory	*Hopkins Verbal Learning Test – Revised [15]
	*Brief Visuospatial Memory Test – Revised [16]
Functional Status	Medication Management Test – Revised [2]
	University of California San Diego Performance-based Skills Assessment [74, 70]
*Note: Measures used to establish eligibility are marked with an asterisk.	

731

732

Table 2. Baseline characteristics of treatment groups

	Active + CT (n =16)		Sham + CT (n = 15)		Control (n = 15)	
	Mean	SD	Mean	SD	Mean	SD
Gender	13 Men, 3 Women		13 Men, 2 Women		11 Men, 4 Women	
Race	5 White, 11 Black		7 White, 8 Black		5 White, 10 Black	
Age (years)	57.06	4.99	58.80	4.13	61.07	6.28
Education (years)	11.94	3.45	14.00	3.59	13.33	3.39
WTAR VIQ <sup>a</sup>	96.75	14.56	102.40	16.10	95.93	14.84
WAIS-IV Forward <sup>b</sup>	8.31	1.66	9.67	2.13	8.27	2.22
WAIS-IV Backward	6.56	1.55	7.53	2.75	7.00	1.93
WAIS-IV Sequence	7.44	1.97	7.73	2.69	6.93	1.98
WAIS-IV Total	22.31	3.96	24.93	6.75	22.2	4.92
WMS-IV Symbol Span	16.13	5.10	16.07	7.42	12.53	4.05
Simple Reaction Time (ms)	638.31	123.37	620.87	127.66	653.84	122.89
Choice Reaction Time (ms)	538.63	99.33	523.33	90.75	542.64	122.29
HVLT Total	21.69	3.16	20.40	5.90	19.53	3.83
HVLT Delayed	6.81	2.56	6.47	2.48	5.60	2.50
BVMT Total	14.50	4.66	15.13	8.63	11.80	6.93
BVMT Delayed	6.38	2.78	6.40	3.46	4.53	3.44
Trails A	42.81	16.37	43.93	20.10	46.20	11.01
Trails B	98.88	33.40	117.53	40.20	117.73	37.45
Pegs R	99.50	22.96	94.73	21.35	101.47	23.05
WAIS-IV Coding	48.94	9.28	51.67	13.70	46.07	15.52
Stroop	29.69	6.98	32.27	9.66	24.80	9.87
IGT	-6.67	22.84	7.73	26.70	-4.67	29.51
MMT	11.94	2.59	13.53	3.56	11.53	4.53
UPSA	79.75	10.71	80.20	16.40	76.73	13.72

733 <sup>a</sup>WTAR VIQ = Wechsler Test of Adult Reading estimated verbal IQ;

734 <sup>b</sup>WAIS-IV Forward = Wechsler Adult Intelligence Scale, 4<sup>th</sup> Ed (WAIS-IV) Digit Span  
 735 Forward subtest; WAIS-IV Backward = WAIS-IV Digit Span Backward subtest; WAIS-IV  
 736 Sequence = WAIS-IV Sequencing subtest; WAIS-IV Total = WAIS-IV Digit Span total of

737 three subtests; WMS-IV Symbol = Wechsler Memory Scale, 4<sup>th</sup> ed, Symbol Span subtest;  
738 Simple Reaction Time = California Computerized Assessment Package Simple Reaction  
739 task; Choice Reaction Time = California Computerized Assessment Package Choice  
740 Reaction task; HVLT Total = Hopkins Verbal Learning Test total score; HVLT Delayed =  
741 Hopkins Verbal Learning Test delayed recall score; BVMT Total = Brief Visuospatial  
742 Memory Test--Revised total score; BVMT Delayed = Brief Visuospatial Memory Test--  
743 Revised delayed recall score; Trails A = Trail Making Test, Part A; Trails B = Trail Making  
744 Test, Part B; Pegs R = Grooved Pegboard, right hand performance; WAIS-IV Coding =  
745 WAIS-IV Coding subtest; Stroop = Stroop Color-Word test score; IGT = Iowa Gambling  
746 Task Net Total score; Verbal Fluency = DKEFS Category Fluency subtest; Design Fluence  
747 = DKEFS Design Fluency subtest; MMT = Medication Management Test—Revised score;  
748 UPSA Total = UCSD Performance-Based Skills Assessment; subtest.

749

Table 3. Likelihood ratio test and effect sizes for the interaction of group by time


	$\chi^2$	df	<i>p</i>	<i>d</i>
WAIS-IV Forward <sup>a</sup>	9.03	4	<b>0.06</b>	0.99
WAIS-IV Backward	2.56	4	0.82	0.38
WAIS-IV Sequence	4.06	4	0.40	0.62
WAIS-IV Total	6.55	4	0.16	0.82
WMS-IV Symbol Span	2.79	4	0.59	0.51
Simple Reaction Time	0.19	4	0.66	0.13
Choice Reaction Time	0.29	4	0.59	0.16
Trails A	1.14	4	0.89	0.32
Trails B	3.85	4	0.43	0.60
Pegs R <sup>b</sup>	4.54	4	0.34	(0.66)
WAIS-IV Coding	11.80	4	<b>0.02</b>	1.17
HVLT Total	4.37	4	0.36	0.65
HVLT Delayed	2.13	4	0.71	0.44
BVMT Total (note)	6.86	4	0.14	0.84
BVMT Delayed	0.81	4	0.94	0.27
Stroop	9.64	4	<b>0.046</b>	1.03
IGT Net Total	5.34	4	0.25	0.73
Verbal Fluency	5.84	4	0.21	0.76
Design Fluency	5.94	4	0.20	0.77
MMT	2.30	4	0.68	0.46
UPSA Total	2.40	4	0.66	0.02

750 <sup>a</sup>WAIS-IV Forward = Wechsler Adult Intelligence Scale, 4<sup>th</sup> Ed (WAIS-IV) Digit Span  
 751 Forward subtest; WAIS-IV Backward = WAIS-IV Digit Span Backward subtest; WAIS-IV  
 752 Sequence = WAIS-IV Sequencing subtest; WAIS-IV Total = WAIS-IV Digit Span total of  
 753 three subtests; WMS-IV Symbol = Wechsler Memory Scale, 4<sup>th</sup> ed, Symbol Span subtest;  
 754 Simple Reaction Time = California Computerized Assessment Package Simple Reaction




755 task; Choice Reaction Time = California Computerized Assessment Package Choice  
756 Reaction task; HVLN Total = Hopkins Verbal Learning Test total score; HVLN Delayed =  
757 Hopkins Verbal Learning Test delayed recall score; BVMT Total = Brief Visuospatial  
758 Memory Test--Revised total score; BVMT Delayed = Brief Visuospatial Memory Test--  
759 Revised delayed recall score; Trails A = Trail Making Test, Part A; Trails B = Trail Making  
760 Test, Part B; Pegs R = Grooved Pegboard, right hand performance; WAIS-IV Coding =  
761 WAIS-IV Coding subtest; Stroop = Stroop Color-Word test score; IGT = Iowa Gambling  
762 Task Net Total score; Verbal Fluency = DKEFS Category Fluency subtest; Design Fluence  
763 = DKEFS Design Fluency subtest; MMT = Medication Management Test—Revised score;  
764 UPSA Total = UCSD Performance-Based Skills Assessment; subtest.

765



# WAIS Digit Span Forward



Evaluations

